Clinical trials: Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis, Relapsing-Remitting
Phase I BP Interferon (IFN) Beta-001
Phase I study aiming at: assessing the absolute bioavailability, pharmacokinetic profile, and dose proportionality of interferon beta-1a (HSA-free solution in pre-filled syringes) after i.v. and s.c.
- Trial name
- NCT02515695
- Testing
- Interferon beta-1a
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Multiple Sclerosis
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
The purpose of this study is to determine whether glatiramer acetate (Copaxone) will induce anti-inflammatory type II monocyte development during treatment of MS, and if these antigen presenting cells (APC) will promote Th2 and…
- Trial name
- NCT00819195
- Testing
- Glatiramer acetate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Anxiety
Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis
It is a multicentric randomized and controlled study comparing a Scheme therapy program versus local practice in RRMS patients with anxiety.
- Trial name
- NCT04030819
- Testing
- schema therapy
- Where
- France
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Paris Nanterre University
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Relapsing-Remitting Multiple Sclerosis
Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
The primary objective of this study is to assess the effect of natalizumab compared to fingolimod on the evolution of new on-treatment T1-gadolinium-enhancing (Gd+) lesions to persistent black holes (PBH) over 52 weeks.
- Trial name
- REVEAL (NCT02342704)
- Testing
- natalizumab, fingolimod
- Where
- 42 sites in United States, Australia and 7 more
- Volunteers
- 111 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis
This is an exploratory study, which allows analysis of multiple immune parameters derived from peripheral blood mononuclear cells (PBMCs) from patients with relapsing remitting multiple sclerosis before and during…
- Trial name
- DIMAT-MS (NCT02461069)
- Testing
- Dimethyl fumarate
- Where
- 6 sites in Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Multiple Sclerosis
Multiple Sclerosis and Respiratory and Functional Capacity
It is known that respiratory functions, physical activities and functional capacities of Multiple Sclerosis (MS) patients decrease with the progression of the disease.
- Trial name
- NCT05697523
- Testing
- Expanded Disability Status Scale, pulmonary function test, International Physical Activity Questionnaire - Short Form, 6 minute walk test
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Nigde Omer Halisdemir University
Multiple Sclerosis, Relapsing-Remitting
Healthy Volunteer Study Using 3 Different Formulations of Firategrast
This study will investigate how 3 types of drug formulations are absorbed by the body. This study is termed 'open-label', which means volunteers will be aware of which treatment they are receiving.
- Trial name
- NCT01416363
- Testing
- Firategrast immediate release tablet, Firategrast modified release tablet, Firategrast gastro-retentive solution
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Relapsing Remitting Multiple Sclerosis, Fatigue
Correlation Between Daily Physical Activity and Disability, Fatigue, Cognition and Quality of Life in MS Patients
The main purpose of the study is to assess the fatigue, cognition, quality of life and disability correlation to MS-patients daily physical activity.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Fatigue, Quality of Life, Physical Activity
- Trial name
- PAMS (NCT04115930)
- Testing
- Physical Activity measurement:
- Where
- 4 sites in Finland
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- University of Eastern Finland
Multiple Sclerosis, Relapsing-Remitting
An Examination of Cognitive Fatigue Using Functional Neuroimaging
The purpose of this research study is to investigate the effectiveness of MS Disease modifying medications on cognitive fatigue in persons with relapsing remitting multiple sclerosis (RRMS).
- Trial name
- NCT04885894
- Testing
- Zeposia
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Kessler Foundation
Multiple Sclerosis
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
The purpose of this study is to evaluate the feasibility of [18F]Florbetapir positron emission tomography (PET) for assessment of demyelination in the patients with relapsing remitting multiple sclerosis.
- Trial name
- NCT01767493
- Testing
- [18F]Florbetapir PET imaging
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Relapsing-Remitting Multiple Sclerosis (RRMS), Neuromyelitis Optica
Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study
This is a prospective non interventional study including patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or with Neuromyelitis Optica Spectrum Disorders (NMOSD) and healthy subjects, who are enrolled within the…
- Conditions
- Relapsing-Remitting Multiple Sclerosis (RRMS), Neuromyelitis Optica, Healthy
- Trial name
- NCT05245344
- Testing
- Peripheral blood withdrawal
- Where
- 3 sites in Italy
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
RELAPSING REMITTING MULTIPLE SCLEROSIS
Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.
The purpose of this research is to characterize the effect of teriflunomide on the activation of B-cells, as well as its capacity to modify B-cell cytokine secretion.
- Trial name
- NCT02833714
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Multiple Sclerosis, Relapse
Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
This is a multi-center, prospective, controlled study. MS patients (1° group: 30 patients in relapse; 2° group: 30 patients in remission) and age/sex-matched healthy controls (3° group: 30 subjects) will be enrolled in the study.
- Trial name
- NCT04380220
- Testing
- Blood samples and processing
- Where
- 3 sites in United States, Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Relapse Remitting Multiple Sclerosis
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
The purpose of this research is to find out how the T regulatory (Treg) cells control autoimmune response in multiple sclerosis.
- Trial name
- NCT04857489
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Pediatric Multiple Sclerosis
Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis
The purpose of this study is to better understand multiple sclerosis (MS) in children and adolescents, to learn if it differs from adult MS and to investigate if genes or environmental exposures or a combination of both put…
- Trial name
- NCT01396343
- Where
- 17 sites in United States
- Volunteers
- 1,276 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Relapsing-Remitting Multiple Sclerosis
fMRI Study of Treatment Recommendations Comparing Recently Diagnosed Multiple Sclerosis (MS) Patients to Controls
Impaired short term memory, attention and concentration lapses, and slower processing of information occur in up to 40-65% of patients with Multiple Sclerosis (MS).
- Trial name
- NCT00391352
- Testing
- IFN-β-1a (Rebif®)
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Waukesha Memorial Hospital
Multiple Sclerosis
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population…
- Trial name
- GASWI (NCT01695434)
- Testing
- MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
Multiple Sclerosis, Relapsing-Remitting
Cognition and MRI Markers in MS Patients With Aubagio® Treatment
Cognitive impairment is nowadays more and more recognized as an important feature of the multiple sclerosis (MS) disease which contributes largely to disability.
- Trial name
- AUBACOG (NCT03768648)
- Testing
- Clinical assessment, Ecological evaluation, Neuropsychological evaluation
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University Hospital, Bordeaux
Relapsing Remitting Multiple Sclerosis
Productive Value of Sonographic Measurement of Optic Nerve in Transitional Multiple
1.to evaluate the potential role of the optic nerve diameter ( OND determined by ultrasonography and and visual nerve function by visual evoked potential as a biomarker of early axonal loss and disability in patients with…
- Trial name
- NCT06435962
- Testing
- sonography
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University